Alvelestat
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Alvelestat, covering 2022-04-14 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]